These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32571819)

  • 41. Amikacin nephrotoxicity in the rat.
    Houghton DC; Plamp CE; Gilbert DN; Kohlhepp SJ; Bennett WM; Porter GA; DeFehr J; Webb M
    J Environ Pathol Toxicol; 1980 Nov; 4(5-6):277-91. PubMed ID: 7217852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity.
    Nagai J; Takano M
    Drug Metab Pharmacokinet; 2004 Jun; 19(3):159-70. PubMed ID: 15499183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.
    Zasowski EJ; Murray KP; Trinh TD; Finch NA; Pogue JM; Mynatt RP; Rybak MJ
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084753
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In utero aminoglycosides-induced nephrotoxicity in rat neonates.
    Mallié JP; Coulon G; Billerey C; Faucourt A; Morin JP
    Kidney Int; 1988 Jan; 33(1):36-44. PubMed ID: 3352159
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Circadian variations of amikacin nephrotoxicity in rats].
    Dorian C; Cambar J
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):587-90. PubMed ID: 3534748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms and pharmacokinetic/pharmacodynamic profiles underlying the low nephrotoxicity and ototoxicity of etimicin.
    Yao L; Zhang JW; Chen B; Cai MM; Feng D; Wang QZ; Wang XY; Sun JG; Zheng YW; Wang GJ; Zhou F
    Acta Pharmacol Sin; 2020 Jun; 41(6):866-878. PubMed ID: 31937930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aminoglycosides use in patients over 75 years old.
    Fraisse T; Gras Aygon C; Paccalin M; Vitrat V; De Wazieres B; Baudoux V; Lechiche C; Vicens A; Sotto A; Pagani L; Gaillat J; Forestier E; Gavazzi G
    Age Ageing; 2014 Sep; 43(5):676-81. PubMed ID: 24590569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective effect of aminoguanidine against nephrotoxicity induced by amikacin in rats.
    Parlakpinar H; Koc M; Polat A; Vardi N; Ozer MK; Turkoz Y; Acet A
    Urol Res; 2004 Aug; 32(4):278-82. PubMed ID: 15278326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Once-daily dosing of aminoglycosides.
    Blaser J; König C
    Eur J Clin Microbiol Infect Dis; 1995 Dec; 14(12):1029-38. PubMed ID: 8681976
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function.
    Sweileh WM
    Fundam Clin Pharmacol; 2009 Aug; 23(4):515-20. PubMed ID: 19709328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of Spirulina platensis and ascorbic acid on amikacin-induced nephrotoxicity in rabbits.
    Abdel-Daim MM; Ahmed A; Ijaz H; Abushouk AI; Ahmed H; Negida A; Aleya L; Bungau SG
    Environ Sci Pollut Res Int; 2019 Mar; 26(8):8080-8086. PubMed ID: 30685861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides.
    Raveh D; Kopyt M; Hite Y; Rudensky B; Sonnenblick M; Yinnon AM
    QJM; 2002 May; 95(5):291-7. PubMed ID: 11978900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploring the Relationship between FEV
    Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
    Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity.
    Contreras AM; Gamba G; Cortés J; Santiago Y; Nares F; Jimenez-Sanchez G; Bobadilla J; López G; Valadez A; Espinosa A
    Antimicrob Agents Chemother; 1989 Jun; 33(6):973-6. PubMed ID: 2764548
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity?
    Zhanel GG; Ariano RE
    Ren Fail; 1992; 14(1):1-9. PubMed ID: 1561384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aminoglycoside toxicity in infants and children.
    McCracken GH
    Am J Med; 1986 Jun; 80(6B):172-8. PubMed ID: 3524215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Behavior of amikacin in renal parenchyma of normal rats and of rats with acute obstructive renal insufficiency.
    Rudhardt M; Fabre J
    Nephron; 1979; 24(6):287-91. PubMed ID: 514429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Basis for an adequate dosage of aminoglycoside antibiotics.
    Lüthy R
    Infection; 1980; Suppl 1():58-61. PubMed ID: 7399715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Therapeutic monitoring of amikacin and gentamicin in routine clinical practice].
    Kacířová I; Grundmann M
    Vnitr Lek; 2015 Jan; 61(1):33-41. PubMed ID: 25693614
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides.
    Meyer RD
    Am J Med; 1986 Jun; 80(6B):119-25. PubMed ID: 3524214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.